| In Vitro | In vitro activity: Ammonium glycyrrhizinate (AG) prepared from glycyrrhizin dramatically protects AGS cells from H(2)O(2)-induced damage as measured by the integrity of actin cytoskeleton. AG also inhibits FeSO(4)-induced reactive oxygen radicals in a dose-dependent manner, suggesting the role for AG as a free radical scavenger. |
|---|
| In Vivo | Ammonium glycyrrhizinate (28 mg/kg) leads to changes in the activity of some enzymes in the brain, the development of parenchymatous dystrophy of the liver which changed to acidophilic necrosis attended with signs of regeneration in mice and rats model. Ammonium glycyrrhizinate-loaded nonionic surfactant vesicles (NSVs) decreases edema and nociceptive responses when compared with Ammonium glycyrrhizinate alone and empty NSVs in mice model. Ammonium glycyrrhizinate up-regulates interleukin-10 (IL-10) level and down-regulates the tumor neurosis factor-α (TNF-α) level and inhibits the cyclic adenosine monophosphate-phosphodiesterase (cAMP-PDE) activity in the lung tissue of mice. Ammonium glycyrrhizinate -loaded non-ionic surfactant vesicles shows no toxicity, good skin tolerability and are able to improve the drug anti-inflammatory activity in mice. Ammonium glycyrrhizinate significantly decreases triglyceride, cholesterol, low density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels in rats. Ammonium glycyrrhizinate increases high density lipoprotein (HDL) levels increased in rats. |
|---|
| Animal model | Mice and rats
|
|---|
| Formulation & Dosage | 28 mg/kg |
|---|
| References | Exp Biol Med (Maywood). 2009 Mar;234(3):263-77; Eksp Klin Farmakol. 1997 Mar-Apr;60(2):65-7; Int J Nanomedicine. 2014 Jan 24;9:635-51. |
|---|
m.cnreagent.com